Sign In
Buy IONS
$73.82
+0.85 (+1.16%)
At Close: Jun 03, 2026
Biogen, Ionis to discontinue development of ALS drug
07:41am, Thursday, 16'th May 2024
Biogen and Ionis Pharmaceuticals said on Thursday they will terminate the development of their experimental treatment for amyotrophic lateral sclerosis (ALS) after failing to show improvement in patie
Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
07:30am, Thursday, 16'th May 2024
Development of BIIB105, an investigational antisense oligonucleotide for amyotrophic lateral sclerosis (ALS), will be discontinued based on data from the Phase 1/2 ALSpire study Biogen and Ionis cont
Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome
07:00am, Thursday, 16'th May 2024
ION582 demonstrated consistent improvements across multiple functional domains in Angelman syndrome patients ION582 was safe and well tolerated at all dose levels Ionis plans to move ION582 into pivot
Ionis to host 2024 virtual Annual Meeting of Stockholders
07:05am, Wednesday, 15'th May 2024
CARLSBAD, Calif. , May 15, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2024 virtual Annual Meeting of Stockholders followed by a ge
The 3 Most Undervalued Pharma Stocks to Buy in May 2024
06:30am, Thursday, 09'th May 2024
Here's a question for you: What determines the value of a drug? Is it the number of lives it saves or how much it costs to make?
Ionis (IONS) Q1 Loss Narrower Than Expected, Sales Miss
11:42am, Wednesday, 08'th May 2024
Ionis (IONS) posts mixed first-quarter 2024 results. The company continues to focus on pipeline development.
Ionis Pharmaceuticals, Inc. (IONS) Q1 2024 Earnings Call Transcript
05:39pm, Tuesday, 07'th May 2024
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q1 2024 Results Conference Call May 7, 2024 11:30 AM ET Company Participants Wade Walke - SVP of IR Brett Monia - CEO Kyle Jenne - Chief Global Product Strat
Ionis Pharmaceuticals (IONS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
10:36am, Tuesday, 07'th May 2024
The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall S
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Misses Revenue Estimates
09:11am, Tuesday, 07'th May 2024
Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.98 per share versus the Zacks Consensus Estimate of a loss of $1.10. This compares to loss of $0.87 per share a year ago.
Ionis reports first quarter 2024 financial results
07:00am, Tuesday, 07'th May 2024
WAINUA TM launch on track; EU and Canada approval decisions expected this year Olezarsen NDA submitted to FDA for FCS; preparing EU regulatory submission Positive Phase 3 donidalorsen data for HAE;
Wall Street's Insights Into Key Metrics Ahead of Ionis Pharmaceuticals (IONS) Q1 Earnings
10:22am, Monday, 06'th May 2024
Get a deeper insight into the potential performance of Ionis Pharmaceuticals (IONS) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the esti
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
11:06am, Tuesday, 30'th Apr 2024
Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ionis Publishes 2023 Corporate Responsibility Report
07:00am, Thursday, 25'th Apr 2024
Established new corporate responsibility strategic pillars and actionable goals Received approval for two Ionis-discovered medicines in 2023, and continued to advance a broad pipeline poised to bring
Ionis to hold first quarter 2024 financial results webcast
07:05am, Tuesday, 23'rd Apr 2024
Webcast scheduled for Tuesday, May 7 at 11:30 a.m. Eastern Time CARLSBAD, Calif.
Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome
09:48am, Sunday, 07'th Apr 2024
– Olezarsen met the primary endpoint with statistically significant reduction of fasting triglycerides and showed substantial, clinically meaningful reduction in acute pancreatitis e
